Company intelligence / Profile preview
NovoMedix
San Diego, California, United Statesnovomedix.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Preclinical
01
Overview
NovoMedix has developed small molecule therapeutics that inhibit IL-11 expression, demonstrating efficacy in animal models of liver, lung, and cardiac fibrosis; prevention of tumor growth and metastasis; prevention of chemotherapy-induced cardiotoxicity in triple negative breast cancer; and improvement in glucose homeostasis in diabetes. The company is poised to begin IND enabling studies for its lead product targeting treatment and prevention of cardiotoxicity in triple negative breast cancer.
- Therapeutic areas
- OtherOncologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on NovoMedix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NovoMedix.